Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      Chemoradiotherapy*; Carcinoma/*pathology ; Carcinoma/*therapy ; Nasopharyngeal Neoplasms/*pathology ; Nasopharyngeal Neoplasms/*therapy; Adult ; Chemotherapy, Adjuvant ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Nasopharyngeal Carcinoma ; Neoplasm Staging ; ROC Curve ; Risk Factors ; Survival Analysis
    • نبذة مختصرة :
      The present study aimed to define high-risk patients who may benefit from additional adjuvant chemotherapy (AC) after concurrent chemotherapy in combination with intensity-modulated radiotherapy among patients with loco-regionally advanced nasopharyngeal carcinoma (NPC). A cohort of 511 NPC patients who received concomitant chemoradiotherapy (CCRT) with or without AC between January 2007 and December 2012 were retrospectively analysed. One hundred seventy-seven patients received CCRT alone, whereas 334 received CCRT + AC. The survival analysis showed that ages >45 years old, T3-T4 stages, N2-N3 disease and serum albumin levels ≤42 g/L were significant independent prognostic factors for overall survival (OS). Using these four risk factors, a prognostic model for OS was created as follows: (1) low-risk group: 0-1 risk factors; and (2) high-risk group: 2-4 risk factors. In the CCRT alone and CCRT + AC groups, significant differences in survival were found between the high- and low-risk groups. Patients in the high-risk group exhibited improved OS due to the addition of AC to CCRT, but no survival benefits were found in the low-risk group. In conclusion, high-risk patients may benefit from the addition of AC to CCRT regarding OS.
      Competing Interests: The authors declare no competing financial interests.
    • References:
      J Clin Oncol. 2004 Jul 1;22(13):2643-53. (PMID: 15226332)
      Oncotarget. 2016 Mar 22;7(12):13612-20. (PMID: 26871291)
      BMC Cancer. 2013 May 04;13:226. (PMID: 23642234)
      Curr Oncol. 2014 Jun;21(3):e408-17. (PMID: 24940100)
      Head Neck. 2014 May;36(5):660-6. (PMID: 23606535)
      Oncotarget. 2016 Feb 2;7(5):6221-30. (PMID: 26716900)
      PLoS One. 2016 Apr 27;11(4):e0154501. (PMID: 27119991)
      Ann Oncol. 2015 Jan;26(1):205-211. (PMID: 25355717)
      Sci Rep. 2015 Nov 13;5:16664. (PMID: 26564805)
      Oral Oncol. 2015 Mar;51(3):254-9. (PMID: 25467207)
      PLoS One. 2016 Jul 11;11(7):e0158853. (PMID: 27399281)
      Am J Clin Oncol. 2015 Apr;38(2):189-96. (PMID: 23608833)
      Sci Rep. 2016 Feb 29;6:22000. (PMID: 26924234)
      Lancet Oncol. 2012 Feb;13(2):163-71. (PMID: 22154591)
      Tumour Biol. 2013 Jun;34(3):1729-36. (PMID: 23436047)
      Eur J Cancer. 2015 Aug;51(12):1570-9. (PMID: 26044925)
      CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
      Radiat Oncol. 2013 Nov 13;8:265. (PMID: 24219818)
    • الموضوع:
      Date Created: 20170203 Date Completed: 20181024 Latest Revision: 20240324
    • الموضوع:
      20240324
    • الرقم المعرف:
      PMC5288719
    • الرقم المعرف:
      10.1038/srep41449
    • الرقم المعرف:
      28150694